ESHRE 2019 promises another feast of science with 1854 abstract submissions, a hot invited programme now in place, and 16 precongress courses.

ESHRE Chairman Roy Farquharson describes the outcome of a two-year strategic review which aims to enhance member support in five key areas of ESHRE activity.

HPV infection is common and long lasting, especially in men, and it may provide one explanation for some of what has so far been classified as 'unexplained' infertility.

Registry studies provide unequivocal evidence of both short- and long-term health risks in ART offspring born from multiple pregnancies. SET and vitrification now provide the means to reduce the risks.

Thomas Ebner from the local organising committee of this year's Annual Meeting in Vienna previews its programme, noting that the opening keynote lectures are likely to be heard by an audience of more than 4000 delegates.

Professor Chris Barratt, former editor of Molecular Human Reproduction and a former co-ordinator of the SIG Andrology, talks to Focus on Reproduction about preconceptional and in utero factors in the determination of male infertility and future general health.

Professor Allan Pacey, a former chairman of the British Fertility Society, took part in a debate in New York on the place of semen analysis in the treatment male infertility today. He talked to Focus on Reproduction about the relevance of diagnostic approaches in male factor cases and the future directions which andrology seems likely to take.

As another meta-analysis finds only limited outcome benefit from frozen embryo transfers, US data indicate that 25% of all cycles in 2016 were freeze-all.

There is strong evidence of a fetal and even preconceptional origin to male reproductive and general health. A Campus meeting in March reviewed the evidence and underlined the importance of male infertility as a marker of future health.

Despite accumulating evidence from meta-analyses and randomised trials, Abha Maheshwari, who is leading the nearly completed E-Freeze study in the UK, argues that the advantages of a freeze-all strategy in embryo transfer are still evident only in selected patients - those at risk of OHSS, hyper-responders, and those with a good prognosis.